Supernus Pharmaceuticals ...

NASDAQ: SUPN · Real-Time Price · USD
42.34
0.17 (0.40%)
At close: Aug 15, 2025, 10:01 AM

Supernus Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
165.45M 149.82M 174.16M 175.69M 168.32M 143.64M 164.31M 153.88M 135.56M 153.76M 167.33M 177.35M 170.05M 152.51M 159.05M 148.46M 141.33M 130.93M
Cost of Revenue
38.15M 15.76M 26.1M 17.58M 38.62M 37.06M 41.3M 19.6M 21.09M 23.46M 22.95M 25.88M 20.46M 17.93M 16.99M 18.09M 25.03M 14.95M
Gross Profit
127.31M 134.06M 148.06M 138.02M 129.7M 106.59M 123.01M 134.28M 114.47M 130.3M 144.37M 151.47M 149.59M 134.57M 142.06M 130.38M 116.3M 115.98M
Operating Income
11.14M -10.26M 21.41M 40.84M 18.21M -4.25M 18.99M 8.14M -17.59M 8.88M 34.33M 1.77M 11.35M 17.33M 6.1M 32.6M 34.11M 13.21M
Interest Income
4.53M 4.42M 4.98M 4.1M 3.73M 3.4M 1.99M 1.75M 1.37M 5.35M 2.4M 2.8M 1.79M 14.7M 1.89M 2.28M 2.59M 3.81M
Pretax Income
16.67M -5.83M 26.38M 44.94M 26.3M 243K 990K 9.89M -17.13M 9.02M 35.14M -444K 11.32M 14.72M 2.05M 28.96M 31.23M 10.93M
Net Income
22.5M -11.83M 15.33M 38.5M 19.92M 124K 1.18M -15.98M -831K 16.95M 25.48M 1.75M 7.87M 25.62M 2.44M 21.56M 23.73M 5.69M
Selling & General & Admin
94.55M 89.94M 79.41M 69.75M 85.9M 86.52M 81.28M 82.7M 86.78M 85.6M 73.97M 112.31M 100.48M 90.46M 101.73M 72.03M 69.53M 61.46M
Research & Development
21.61M 26.93M 28.05M 29.04M 25.58M 24.32M 22.74M 22.66M 24.38M 21.21M 17.77M 19.55M 16.39M 20.84M 21.08M 19.65M 15.46M 34.28M
Other Expenses
n/a 27.45M 18.6M n/a n/a n/a n/a n/a n/a 19.97M 20.7M 20.64M n/a 20.64M 12.03M 6.01M 5.95M 6.01M
Operating Expenses
116.17M 144.32M 126.66M 98.19M 111.49M 110.83M 104.02M 126.6M 131.27M 126.78M 112.44M 152.51M 137.5M 131.94M 134.84M 97.69M 90.94M 101.74M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a 910K 1.5M 1.59M 1.72M 1.81M 1.94M 5.93M 5.92M 5.47M 6.1M
Selling & Marketing Expenses
n/a 26.1M 21M 19.6M 58.8M 59.57M 55.28M 56.78M 59.89M 57.23M 47.99M 85.7M 73.58M 60.51M 62.18M 50.7M 48.38M 38.45M
Cost & Expenses
154.31M 160.08M 152.75M 134.84M 150.11M 147.89M 145.32M 146.2M 152.36M 150.24M 135.4M 178.39M 157.96M 149.87M 151.83M 115.78M 115.97M 116.7M
Income Tax Expense
-5.83M 6M 11.05M 6.45M 6.39M 119K -185K 25.86M -16.3M -7.93M 9.66M -2.19M 3.46M -10.89M -391K 7.4M 7.51M 5.24M
Shares Outstanding (Basic)
56.02M 55.87M 55.47M 55.15M 54.98M 54.8M 54.65M 54.61M 54.5M 54.38M 54.1M 53.79M 53.43M 59.35M 53.24M 53.19M 53.01M 52.93M
Shares Outstanding (Diluted)
56.64M 55.87M 56.47M 56.02M 55.72M 55.63M 55.3M 54.61M 54.5M 62.45M 62.09M 55.03M 61.4M 61.41M 54.53M 54.33M 54.72M 54.2M
EPS (Basic)
0.40 -0.21 0.28 0.70 0.36 0.00 0.02 -0.29 -0.02 0.31 0.47 0.03 0.15 0.43 0.05 0.41 0.45 0.11
EPS (Diluted)
0.40 -0.21 0.27 0.69 0.36 0.00 0.02 -0.29 -0.02 0.29 0.41 0.03 0.14 0.42 0.04 0.40 0.43 0.11
EBITDA
37.99M 17.79M 45.23M 65.03M 38.92M 16.5M 40.66M 29.54M 4.49M 24.13M 58.13M 23.05M 33.65M 23.99M 20.71M 41.49M 43.35M 23.63M
EBIT
16.67M -2.6M 26.38M 44.94M 26.3M 243K 18.99M 7.68M -16.22M 3.53M 36.73M 1.28M 12.09M 2.63M 7.99M 34.88M 36.7M 17.03M
Depreciation & Amortization
21.32M 20.38M 18.84M 20.1M 20.71M 20.75M 21.68M 21.86M 20.71M 20.6M 21.4M 21.77M 21.56M 21.36M 12.72M 6.61M 6.65M 6.61M